Sugi Predict

Sugi Predict / Compounds / SCHEMBL1553363

SCHEMBL1553363

SCHEMBL1553363

CC(C)(C)OC(=O)N[C@@H](CO)c1ccc(O)cc1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 3/20 0.47
▸ CTSK P43235 2/20 0.47
▸ MIF P14174 1/20 0.44
▸ RIPK1 Q13546 1/20 0.44
▸ ESR1 P03372 1/20 0.41
▸ ESR2 Q92731 1/20 0.41
▸ GPR88 Q9GZN0 2/20 0.40
▸ PPARA Q07869 2/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ ATM Q13315 1/20 0.39
▸ PPARG P37231 1/20 0.38
▸ APLNR P35414 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25533312 1.00 CTSS (0.47) CTSSCTSKMIFRIPK1ESR1
SCHEMBL2011973 1.00 CTSS (0.47) CTSSCTSKMIFRIPK1ESR1
SCHEMBL28995700 0.88 PPARG (0.45) CTSSCTSKRIPK1GPR88PPARA
SCHEMBL17619268 0.88 PPARG (0.45) CTSSCTSKRIPK1GPR88PPARA
SCHEMBL25384144 0.87 RIPK1 (0.43) CTSSCTSKRIPK1GPR88CA1
SCHEMBL19580945 0.87 CTSS (0.48) CTSSCTSKRIPK1
SCHEMBL13059067 0.87 CTSS (0.48) CTSSCTSKRIPK1GPR88
SCHEMBL1554097 0.87 CTSS (0.48) CTSSCTSKRIPK1
SCHEMBL14847725 0.87 GAA (0.48) CTSSCTSKRIPK1PPARAPPARG
SCHEMBL1463347 0.87 CTSS (0.48) CTSSCTSKRIPK1GPR88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516053-B2 Bcl-2 inhibitors BEONE MEDICINES I GMBH (CH) 2026-01-06 — — US disclosed
US-20250353853-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-11-20 — — US disclosed
US-12312349-B2 Apoptosis-inducing agents FOCHON PHARMACEUTICALS, LTD. (CN) 2025-05-27 — — US disclosed
EP-4532476-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-04-09 — — EP disclosed
CN-119630645-A Flavivirus inhibitors IRBM股份公司 2025-03-14 — — CN disclosed
US-20240360103-A1 COMPLEMENT INHIBITION SIXTH STREET LENDING PARTNERS 2024-10-31 — — US disclosed
EP-4119560-B1 APOPTOSIS-INDUCING AGENTS FOCHON PHARMACEUTICALS LTD (CN) 2024-06-05 — — EP disclosed
WO-2023227734-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-30 — — WO disclosed
WO-2023227734-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-30 — — WO disclosed
EP-4282862-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-29 — — EP disclosed
US-20150072970-A1 BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS, INC. (US) 2015-03-12 — — US disclosed
US-8895741-B2 Process for the synthesis of biaryl oxazolidinones MELINTA THERAPEUTICS, INC. (US) 2014-11-25 — — US disclosed
CN-104136441-A Gonadotropin-releasing hormone receptor antagonists, process for their preparation and pharmaceutical compositions comprising them SK CHEMICALS CO LTD 2014-11-05 — — CN disclosed
WO-2013129879-A1 GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK CHEMICALS CO., LTD. (KR) 2013-09-06 — — WO disclosed
US-8497271-B2 Modulators of G protein-coupled receptor 88 BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-30 — — US disclosed
EP-2486030-B1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 BRISTOL MYERS SQUIBB CO (US) 2013-07-24 — — EP disclosed
US-20130066076-A1 Process for the Synthesis of Biaryl Oxazolidinones MELINTA SUBSIDIARY CORP. 2013-03-14 — — US disclosed
EP-2486030-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 Bristol-Myers Squibb Company (US) 2012-08-15 — — EP disclosed
US-20110245264-A1 Modulators of G Protein-Coupled Receptor 88 Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. 2011-10-06 — — US disclosed
WO-2011044195-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130066076-A1 Process for the Synthesis of Biaryl Oxazolidinones PCNA, PGC, SBDS CTSS 1609/4885CTSK 1349/4885MIF 36/4885
US-20150072970-A1 BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME PCNA, AADAC, MIF CTSS 320/4885CTSK 817/4885MIF 3/4885
US-12312349-B2 Apoptosis-inducing agents BCL2, BAX, BAD CTSS 1547/4885CTSK 1065/4885MIF 3244/4885
US-20240360103-A1 COMPLEMENT INHIBITION C5, C9, C1QBP CTSS 238/4885CTSK 405/4885MIF 800/4885
US-20110245264-A1 Modulators of G Protein-Coupled Receptor 88 GPR88, GPR68, GRK2 CTSS 4468/4885CTSK 4010/4885MIF 3240/4885
US-20250353853-A1 FLAVIVIRUS INHIBITORS SPINT2, EIF2AK2, DDX5 CTSS 284/4885CTSK 714/4885MIF 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.